B-cell receptor on polyribosylribitol phosphate-specific B lymphocyte (PRP-specific BCR)

The B-cell receptor (BCR) on polyribosylribitol phosphate (PRP)-specific B lymphocytes is a specialized membrane-bound immunoglobulin that recognizes the capsular polysaccharide of Haemophilus influenzae type b (Hib) (CDC, 2021). PRP is the primary virulence factor of Hib, and the interaction between PRP and these specific BCRs is fundamental to the development of protective immunity (Pollard et al., 2009). In clinical practice, this receptor is the primary target of Hib conjugate vaccines, such as ActHIB and PedvaxHIB, which utilize the PRP antigen to stimulate B-cell activation and the subsequent production of neutralizing antibodies (NIH, 2023). Because pure polysaccharide antigens are poorly immunogenic in infants, modern vaccines conjugate PRP to carrier proteins to engage T-cell help, thereby enhancing the BCR-mediated response and inducing long-term memory (Pichichero, 2013). This target is central to preventing severe invasive diseases such as bacterial meningitis and pneumonia in pediatric populations. Monitoring the efficacy of targeting these receptors is typically achieved by measuring serum anti-PRP IgG levels, where a concentration of 0.15 µg/mL is often associated with short-term protection (WHO, 2013).

Other names

PRP-specific B-cell receptorHib-specific B-cell receptorPolyribosylribitol phosphate-specific BCRAnti-PRP B-cell receptor

The PRP-conjugate vaccine binds to the B-cell receptor (BCR) on PRP-specific B lymphocytes, inducing receptor cross-linking and internalization. This process, facilitated by T-cell help via the carrier protein, leads to B-cell activation, proliferation, and differentiation into antibody-secreting plasma cells and memory B cells.